stockrowDefinium Therapeutics, Inc.
DFTX Healthcare Biotechnology
- EPS
- −188.0%
- Free cash flow
- −78.3%
- Total debt
- −11.5%
Quarter to June 2026, against a year earlier
Follow DFTX
Alert me
Definium Therapeutics, Inc. (DFTX) Return on equity
Definium Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −64.1%, down 0.0 percentage points from fiscal 2025 (−64.1%). Over the past ten years it has ranged from −455.5% (fiscal 2019) to −8.20% (fiscal 2016); the current reading is higher than 60% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −64.1% | 3.95 |
| FY2024 | −68.0% | 15.58 |
| FY2023 | −83.6% | (46.05) |
| FY2022 | −37.5% | 44.24 |
| FY2021 | −81.8% | 5.27 |
| FY2020 | −87.1% | 368.43 |
| FY2019 | −455.5% | (433.54) |
| FY2018 | −21.9% | 38.41 |
| FY2017 | −60.4% | (52.15) |
| FY2016 | −8.20% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | 14.9% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| DFTX Definium Therapeutics, Inc. | −64.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)